Therapeutics | Plato. Vertical Search. Ai.

Common bacteria modified to make designer sugar-based drug

Process paves a road to safe, ethical, and fast drug manufacturing Credit: Rensselaer Polytechnic Institute TROY, N.Y. — Envisioning an animal-free drug supply, scientists have —...

Biotechnology3 days ago

MIT team improving gene therapies wins Sloan health care prize

The MIT team Kano Therapeutics won the 2021 Sloan Healthcare Innovations Prize Thursday with its novel approach for producing single-stranded DNA (ssDNA). The technology could make...

PR Newswire4 days ago

Antengene (6996.HK) Selected as a Constituent Stock of Nine Benchmark and Thematic Indexes Including the Hang Seng Composite Index

SHANGHAI and HONG KONG, Feb. 28, 2021 /PRNewswire/ — Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing...

PR Newswire5 days ago

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Pandion Therapeutics, Inc. – PAND

NEW YORK, Feb. 27, 2021 /PRNewswire/ — Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in...

Bioengineer6 days ago

Research reveals how bacteria defeat drugs that fight cystic fibrosis

Credit: UM photo MISSOULA – University of Montana researchers and their partners have discovered a slimy strategy used by bacteria to defeat antibiotics and other drugs...

Bioengineer6 days ago

C-Path and Global Partners launch Ataxia Consortium

The Critical Path to Therapeutics for the Ataxias will optimize clinical trials for inherited ataxias Credit: C-Path TUCSON, Ariz., February 26, 2021 — Critical Path Institute...

PR Newswire6 days ago

ZyVersa Therapeutics’ CSO, Nicholas A. LaBella, Jr., to Present at the 3rd Annual Chronic Kidney Disease Drug Development Summit Being Held Virtually March 2-4, 2021

WESTON, Fla., Feb. 26, 2021 /PRNewswire/ — ZyVersa Therapeutics, Inc. (ZyVersa), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal...

PR Newswire6 days ago

Jubilant Therapeutics annonce une collaboration de recherche avec le Boston Children’s Hospital et la Harvard Medical School pour évaluer les inhibiteurs de PAD4 dans le cadre de maladies auto-immunes/inflammatoires

BEDMINSTER, New Jersey, 26 février 2021 /PRNewswire/ — Jubilant Therapeutics Inc., une société biopharmaceutique qui fait progresser les modulateurs à petites molécules pour répondre aux besoins...

PR Newswire6 days ago

XNK Therapeutics partners with Karolinska Institutet on Phase II study in patients with multiple myeloma with support from Sanofi

STOCKHOLM, Feb. 26, 2021 /PRNewswire/ — XNK Therapeutics AB (“XNK”) today announced that it is entering into a joint Phase II clinical study to treat patients...

PR Newswire6 days ago

Jubilant Therapeutics kündigt Forschungskooperation mit Boston Children’s Hospital, Harvard Medical School, zur Evaluierung von PAD4-Inhibitoren in Autoimmun-/Entzündungskrankheitsmodellen an

BEDMINSTER, New Jersey, 26. Februar 2021 /PRNewswire/ — Jubilant Therapeutics Inc. , ein biopharmazeutisches Unternehmen, das niedermolekulare Modulatoren entwickelt, um ungedeckten medizinischen Bedarf in der Onkologie...